

Product Monograph
Including Patient Medication Information

PrOPDUALAG®

nivolumab and relatlimab for injection

Human IgG4 monoclonal anti-PD-1 and anti-LAG-3 antibody produced in Chinese hamster ovary cells
using recombinant deoxyribonucleic acid technology

Solution for intravenous infusion,

240 mg nivolumab/20 mL (12 mg/mL) and 80 mg relatlimab/20mL (4 mg/mL)

single-use vial

Antineoplastic

Bristol-Myers Squibb Canada
2344 Alfred-Nobel Boulevard, Suite 300
St-Laurent, QC H4S 0A4

Date of Authorization:
2026-09-11

Control Number: 501360

® Registered trademark of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb
Canada

Recent Major Label Changes

7. Warnings and Precautions	2026-01
	2026-06
	2026-09

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes.....	2
Table of Contents	2
Part 1: Healthcare Professional Information	5
1. Indications.....	5
1.1. Pediatrics.....	5
1.2. Geriatrics	5
2. Contraindications	5
3. Serious Warnings and Precautions Box	5
4. Dosage and Administration	6
4.1. Dosing Considerations	6
4.2. Recommended Dose and Dosage Adjustment	6
4.3. Reconstitution	9
4.4. Administration.....	9
4.5. Missed Dose	10
5. Overdose	11
6. Dosage Forms, Strengths, Composition, and Packaging	11
7. Warnings and Precautions	12
General	12
Carcinogenesis and Genotoxicity	12
Driving and Operating Machinery	12
Hematologic	12
Hepatic/Biliary/Pancreatic.....	12
Immune	12

Infusion-Related Reactions	16
Monitoring and Laboratory Tests	16
Renal.....	17
Reproductive Health.....	17
7.1. Special Populations	17
7.1.1. Pregnancy.....	17
7.1.2. Breastfeeding	17
7.1.3. Pediatrics	18
7.1.4. Geriatrics	18
8. Adverse Reactions	18
8.1. Adverse Reaction Overview.....	18
8.2. Clinical Trial Adverse Reactions	19
8.2.1. Clinical Trial Adverse Reactions – Pediatrics	24
8.3. Less Common Clinical Trial Adverse Reactions	24
8.3.1. Less Common Clinical Trial Adverse Reactions – Pediatrics	24
8.4. Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data	25
8.5. Post-Market Adverse Reactions	25
9. Drug Interactions.....	26
9.2. Drug Interactions Overview.....	26
9.3. Drug-Behaviour Interactions	26
9.4. Drug-Drug Interactions.....	26
9.5. Drug-Food Interactions.....	26
9.6. Drug-Herb Interactions.....	26
9.7. Drug-Laboratory Test Interactions	26
10. Clinical Pharmacology	26
10.1. Mechanism of Action.....	26
10.2. Pharmacodynamics	27
10.3. Pharmacokinetics	27
Distribution.....	27
Metabolism.....	27

Elimination.....	28
Special populations and conditions	28
• Pediatrics.....	28
• Hepatic Insufficiency	28
• Renal Insufficiency.....	28
10.4. Immunogenicity.....	29
11. Storage, Stability, and Disposal.....	29
Part 2: Scientific Information	30
13. Pharmaceutical Information	30
14. Clinical Trials.....	30
14.1. Clinical Trials by Indication	31
Unresectable or Metastatic Melanoma	31
16. Non-Clinical Toxicology.....	33
17. Supporting Product Monographs.....	34
Patient Medication Information	35

Part 1: Healthcare Professional Information

1. Indications

OPDUALAG (nivolumab and relatlimab) is indicated for:

Unresectable or Metastatic Melanoma:

- Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma (see [14. Clinical Trials](#)).

1.1. Pediatrics

Pediatrics (< 12 years of age):

The safety and efficacy of Opdualag in pediatrics <12 years of age has not been established. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatrics <12 years of age.

1.2. Geriatrics

Geriatrics (≥65 years of age):

No overall differences in safety or effectiveness were observed between elderly patients (≥65 years) and younger patients (<65 years) (see [7.1.4 Geriatrics](#)).

2. Contraindications

Opdualag is contraindicated in patients who are hypersensitive to nivolumab or relatlimab or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6. Dosage Forms, Strengths, Composition, and Packaging](#).

3. Serious Warnings and Precautions Box

Opdualag can cause severe and fatal immune-mediated adverse reactions, including pneumonitis, acute edema of the lung and hemophagocytic lymphohistiocytosis (HLH) (see [7. Warnings and Precautions](#), Immune-Mediated Adverse Reactions). Severe and fatal immune-mediated adverse reactions have been observed with nivolumab, which is a component of Opdualag. Healthcare professionals should consult the Opdivo (nivolumab) Product Monograph prior to initiation of Opdualag.

Immune-mediated adverse reactions may involve any organ system. While most of these reactions occurred during treatment, onset months after the last dose has been reported (see [7. Warnings and Precautions](#)).

Early diagnosis and appropriate management are essential to minimize potential life-threatening complications. Patients should be monitored for signs and symptoms suggestive of immune-mediated adverse reactions (see [7. Warnings and Precautions](#) and [4. Dosage and Administration](#) for management guidelines for these adverse reactions). Opdualag must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

4. Dosage and Administration

4.1. Dosing Considerations

The recommended Opdualag dosage for pediatric patients who are at least 12 years old and weigh at least 40 kg is the same as for adults. A recommended dose has not been established for pediatric patients who are 12 years or older and weigh less than 40 kg.

4.2. Recommended Dose and Dosage Adjustment

Recommended Dose

The recommended dosage of Opdualag is presented in Table 1.

Table 1: Recommended Dosage and Administration Schedule

Indication	Recommended Dose and Schedule	Duration of Therapy
Unresectable or metastatic melanoma	Adult and Pediatric patients 12 years of age or older and weighing at least 40 kg: 480 mg nivolumab and 160 mg relatlimab every 4 weeks (30-minute intravenous infusion)	Until disease progression or unacceptable toxicity

Recommended Dosage Adjustment

Dose escalation or reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability.

Dosage modifications for adverse reactions that require management different from these general guidelines are summarized in Table 2 (see also [7. Warnings and Precautions](#)).

Table 2: Recommended Treatment Modifications for Opdualag

Target Organ/System	Adverse Reaction ¹	Treatment Modification
Pulmonary	Grade 2 pneumonitis	Withhold dose(s) until symptoms resolve, radiographic abnormalities improve, and management with corticosteroids is complete
	Grade 3 or 4 pneumonitis	Permanently discontinue treatment
Gastrointestinal	Grade 2 or 3 diarrhea or colitis	Withhold dose(s) until symptoms resolve and

		management with corticosteroids, if needed, is complete
	Grade 4 diarrhea or colitis	Permanently discontinue treatment
Hepatic	Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) increases to more than 3 and up to 5 times upper limit of normal (ULN) or Total bilirubin increases to more than 1.5 and up to 3 times ULN.	Withhold dose(s) until laboratory values return to baseline and management with corticosteroids, if needed, is complete
	AST or ALT increases to more than 5 times ULN regardless of baseline. or Total bilirubin increases to more than 3 times ULN. or Concurrent AST or ALT increase to more than 3 times ULN and total bilirubin increase to more than 2 times ULN.	Permanently discontinue treatment
Renal	Grade 2 or 3 creatinine elevation	Withhold dose(s) until creatinine returns to baseline and management with corticosteroids is complete
	Grade 4 creatinine elevation	Permanently discontinue treatment
Endocrine	Symptomatic Grade 2 or 3 hypothyroidism, hyperthyroidism, hypophysitis Grade 2 adrenal insufficiency Grade 3 diabetes	Withhold dose(s) until symptoms resolve and management with corticosteroids (if needed for symptoms of acute inflammation) is complete. Treatment should be continued in the presence of hormone replacement therapy as long as no symptoms are present
	Grade 4 hypothyroidism Grade 4 hyperthyroidism Grade 4 hypophysitis	Permanently discontinue treatment

	Grade 3 or 4 adrenal insufficiency Grade 4 diabetes	
Skin	Grade 3 rash	Withhold dose(s) until symptoms resolve and management with corticosteroids is complete
	Suspected Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or drug rash with eosinophilia and systemic symptoms (DRESS)	Withhold dose(s)
	Grade 4 rash Confirmed SJS, TEN or DRESS	Permanently discontinue treatment
Myocarditis	Grade 2, 3 or 4 myocarditis	Permanently discontinue treatment
Neurological ²	Grade 2	Withhold dose(s) until symptoms resolve and management with corticosteroids, if needed, is complete
	Grade 3 or 4	Permanently discontinue treatment
Infusion-Related Reactions	Grade 1 or 2	Interrupt or slow the rate of infusion
	Grade 3 or 4	Permanently discontinue treatment
Other	Grade 3 (first occurrence)	Withhold dose(s) until symptoms resolve or improve and management with corticosteroids is complete
	Grade 4 or recurrent Grade 3; persistent Grade 2 or 3 despite treatment modification; inability to reduce corticosteroid dose to 10 mg prednisone or equivalent per day	Permanently discontinue treatment

¹ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v 5.0

² Permanently discontinue treatment for demyelinating disease of any grade.

- **Renal Impairment:**

Based on a population pharmacokinetic analysis, no dose adjustment of Opdualag is recommended in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see [10.3 Pharmacokinetics](#)).

- **Hepatic Impairment:**

Based on a population pharmacokinetic analysis, no dose adjustment is required in patients with mild or moderate hepatic impairment. Data from patients with severe hepatic impairment are too limited to draw conclusions on this population (see [10.3 Pharmacokinetics](#)).

- **Geriatric:**

No dose adjustment is required for elderly patients (≥65 years) (see [7.1.4 Geriatrics](#) and see [10.3 Pharmacokinetics](#)).

- **Pediatrics:**

The safety and efficacy of Opdualag have not been established in pediatric patients under the age of 12 years or in pediatric patients 12 years of age or older who weigh less than 40 kg therefore no dosage is recommended (see [7.1.3 Pediatrics](#)).

Use of Opdualag in pediatric patients 12 years of age or older and weighing at least 40 kg is supported by predicted drug exposures at the recommended Opdualag dose that are expected to result in similar safety and efficacy to that of adults.

4.3. Reconstitution

Opdualag is supplied as a clear to opalescent, colorless to slightly yellow solution for intravenous infusion in a single-use vial (see [6. Dosage Forms, Strengths, Composition, and Packaging](#)). For information on administration, and instructions for preparation and use, see [4.4 Administration](#).

Incompatibilities:

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Opdualag should not be infused concomitantly in the same intravenous line with other medicinal products.

4.4. Administration

Opdualag is a fixed-dose combination of nivolumab and relatlimab.

Opdualag is for intravenous use only.

Opdualag is supplied as a single-use vial and does not contain any preservatives.

Preparation

- Visually inspect the Opdualag concentrate for particulate matter or discolouration prior to administration. Opdualag is a clear to opalescent, colourless to slightly yellow solution. Discard the vial if the solution is cloudy, is discoloured, or contains extraneous particulate matter other than a few translucent-to-white particles. Do not shake the vial.
- Use aseptic technique when preparing Opdualag as the product does not contain a preservative.

- Opdualag can be administered undiluted or after dilution.
- Withdraw the required volume of Opdualag concentrate using an appropriate sterile syringe and transfer the concentrate into a sterile, intravenous container (ethylvinyl acetate (EVA), polyvinyl chloride [PVC], or polyolefin).
- If diluting Opdualag prior to administration:
 - Dilute Opdualag solution with either sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection to prepare an infusion meeting the following parameters:
 - The final infusion concentration should range from 3 mg/mL nivolumab and 1 mg/mL relatlimab to 12 mg/mL nivolumab and 4 mg/mL relatlimab.
 - The total infusion volume must not exceed 160 mL, or for adult patients weighing less than 40 kg, the total infusion volume should not exceed 4 mL per kilogram of patient weight.
- Gently mix the infusion by manual rotation. **Do not shake.**

After preparation, store the diluted solution either:

- at room temperature and room light for no more than 8 hours from the time of preparation to the end of the infusion. Discard the prepared solution if not used within 8 hours from the time of preparation;

or

- under refrigeration at 2°C to 8°C (36°F to 46°F) with protection from light for no more than 24 hours from the time of preparation, which includes the time allowed for equilibration of the infusion bag to room temperature and the duration of the infusion.

Discard the prepared solution if not used within 24 hours from the time of preparation.

Do not freeze.

Administration

Opdualag is administered as an intravenous infusion and must not be administered as an intravenous push or bolus injection.

- Administer the infusion over 30 minutes through an intravenous line containing a sterile, non-pyrogenic, low protein binding in-line filter (pore size of 0.2 micrometer to 1.2 micrometer).
- Opdualag infusion is compatible with EVA, PVC and polyolefin containers, PVC infusion sets and in-line filters with polyethersulfone (PES), nylon, and polyvinylidene fluoride (PVDF) membranes with pore sizes of 0.2 micrometer to 1.2 micrometer.
- Do not coadminister other drugs through the same intravenous line.
- After administration of the Opdualag dose, flush the intravenous line with sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection, at end of infusion.

4.5. Missed Dose

If a planned dose of Opdualag is missed, the next dose should be scheduled as soon as possible.

5. Overdose

There is no information on overdosage with Opdualag.

In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition, and Packaging

To help ensure the traceability of biologic products, including biosimilars, health professionals should recognize the importance of recording both the brand name and the non-proprietary (active ingredient) name as well as other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 3 : Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous Infusion	Concentrate for solution for infusion / 240 mg nivolumab/20 mL (12 mg/mL) and 80 mg relatlimab/20 mL (4 mg/mL) single-use vial	Histidine, L-histidine hydrochloride monohydrate, pentetic acid (diethylenetriaminepentaacetic acid), polysorbate 80, sucrose and water for injection.

Opdualag (nivolumab and relatlimab) injection for intravenous use is a fixed dose combination of nivolumab and relatlimab.

Nivolumab is IgG4 kappa monoclonal antibody (mAb) directed against PD-1, a negative T-cell regulator associated with T-cell exhaustion. Nivolumab has a calculated molecular mass of 146 kDa and is expressed in a recombinant CHO cell line.

Relatlimab is a human IgG4 kappa mAb directed against the human LAG-3, a negative T-cell regulator associated with T-cell exhaustion. Relatlimab has a calculated molecular mass of 148 kDa and is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.

Opdualag is a sterile, preservative-free, non-pyrogenic, clear to opalescent, colorless to slightly yellow solution that is essentially free of particles. Opdualag is supplied as 240 mg of nivolumab and 80 mg of relatlimab in a 20 mL single-use vial for intravenous use. Each mL of Opdualag solution contains 12 mg nivolumab, 4 mg relatlimab, and L-histidine (1.1 mg), histidine monohydrochloride monohydrate (2.7 mg), sucrose (85.6 mg), pentetic acid (0.008 mg), polysorbate 80 (0.5 mg), and Water for Injection, USP.

Store Opdualag under refrigeration at 2°C to 8°C (36°F to 46°F). Protect from light by storing in the original package until time of use. Do not freeze or shake.

7. Warnings and Precautions

See [3 Serious Warnings and Precautions Box](#).

General

Opdualag should be administered under the supervision of physicians experienced in the treatment of cancer.

Carcinogenesis and Genotoxicity

The mutagenic and carcinogenic potential of nivolumab or relatlimab have not been evaluated.

Driving and Operating Machinery

Opdualag may have an influence on the ability to drive and use machines. Because of potential adverse reactions such as fatigue, patients should be advised to use caution when driving or operating machinery until they are certain that Opdualag does not adversely affect them.

Hematologic

Hemophagocytic lymphohistiocytosis (HLH)

HLH has been observed with nivolumab as monotherapy, nivolumab in combination with relatlimab and nivolumab in combination with other agents with a fatal event reported in 1/355 patients (0.3%) treated with Opdualag. Patients should be closely monitored. If HLH is suspected, Opdualag should be withheld. If HLH is confirmed, administration of nivolumab in combination with relatlimab should be discontinued and treatment for HLH initiated (see [8. Adverse Reactions](#)).

Hepatic/Biliary/Pancreatic

Hepatic Impairment

The safety and efficacy of Opdualag have not been studied in patients with severe hepatic impairment (see [4. Dosage and Administration](#)).

Immune

Immune-Mediated Adverse Reactions

Immune-Mediated Adverse Reactions (IMARs), which can be severe or fatal, can occur with Opdualag. IMARs affecting more than one body system can occur simultaneously.

Early identification and management of IMARs are essential to minimize potential life-threatening complications. Patients should be monitored continuously (at least up to 5 months after the last dose) as an adverse reaction with Opdualag may occur at any time during or after discontinuation of therapy.

For suspected IMARs, adequate evaluation should be performed to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, Opdualag should be withheld and corticosteroids administered. If immunosuppression with corticosteroids is used to treat an adverse reaction, a taper of at least 1 month duration should be initiated upon improvement. Rapid tapering may lead to worsening or recurrence of the adverse reaction. Non-corticosteroid immunosuppressive therapy should be considered if there is worsening or no improvement despite corticosteroid use.

Opdualag should not be resumed while the patient is receiving immunosuppressive doses of corticosteroids or other immunosuppressive therapy. Prophylactic antibiotics may be used to prevent opportunistic infections in patients receiving immunosuppressive therapy.

Opdualag must be permanently discontinued for any severe IMAR that recurs and for any life-threatening immune-mediated adverse reaction (see [4. Dosage and Administration](#)).

Immune-Mediated Pulmonary Adverse Reactions

Severe pneumonitis or interstitial lung disease, including a fatal case, has been observed with Opdualag (see [8. Adverse Reactions](#)). Patients should be monitored for signs and symptoms of pneumonitis such as radiographic changes (e.g. focal ground glass opacities, patchy infiltrates), dyspnoea, and hypoxia. Infectious and disease-related etiologies should be ruled out.

For Grade 3 or 4 pneumonitis, Opdualag must be permanently discontinued, and corticosteroids should be initiated at a dose of 2 to 4 mg/kg/day methylprednisolone equivalents.

For Grade 2 (symptomatic) pneumonitis, Opdualag should be withheld and corticosteroids initiated at a dose of 1 mg/kg/day methylprednisolone equivalents. Upon resolution of symptoms Opdualag may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 2 to 4 mg/kg/day methylprednisolone equivalents and Opdualag must be permanently discontinued.

Immune-Mediated Gastrointestinal Adverse Reactions

Severe diarrhea or colitis has been observed with Opdualag (see [8. Adverse Reactions](#)). Patients should be monitored for diarrhea and additional symptoms of colitis, such as abdominal pain and mucus and/or blood in stool. Infections and disease-related etiologies should be ruled out. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. Stool infections work-up (including CMV, other viral etiology, culture, Clostridium difficile, ova, and parasite) should be performed upon presentation of diarrhea or colitis to exclude infectious or other alternate etiologies.

For Grade 4 diarrhea or colitis, Opdualag must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

Opdualag should be withheld for Grade 3 diarrhea or colitis, and corticosteroids initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents. Upon resolution of symptoms, Opdualag may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, Opdualag must be permanently discontinued.

For Grade 2 diarrhea or colitis, Opdualag should be withheld. Persistent diarrhea or colitis should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Upon resolution of symptoms, Opdualag may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 1 to 2 mg/kg/day methylprednisolone equivalents and Opdualag must be permanently discontinued.

Addition of an alternative immunosuppressive agent to the corticosteroid therapy, or replacement of the corticosteroid therapy, should be considered in corticosteroid-refractory immune-related colitis if other causes are excluded (including CMV infection/reactivation evaluated with viral PCR on biopsy, and other viral, bacterial, and parasitic etiology).

Immune-Mediated Hepatic Adverse Reactions

Severe hepatitis has been observed with Opdualag (see [8. Adverse Reactions](#)). Patients should be monitored for signs and symptoms of hepatitis such as transaminase and total bilirubin elevations. Infectious and disease-related etiologies should be ruled out.

For AST or ALT increases to more than 5 times ULN regardless of baseline, total bilirubin increases to more than 3 times ULN, or concurrent AST or ALT increase to more than 3 times ULN and total bilirubin increase to more than 2 times ULN, Opdualag must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

For AST/ALT increases to more than 3 and up to 5 times ULN, or total bilirubin increases to more than 1.5 and up to 3 times ULN, Opdualag should be withheld. Persistent elevations in these laboratory values should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Once laboratory values have returned to baseline, Opdualag may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 1 to 2 mg/kg/day methylprednisolone equivalents and Opdualag must be permanently discontinued.

Immune-Mediated Renal Adverse Reactions

Severe nephritis and renal dysfunction have been observed with Opdualag (see [8. Adverse Reactions](#)). Patients should be monitored for signs and symptoms of nephritis or renal dysfunction. Most patients present with asymptomatic increases in serum creatinine. Disease-related etiologies should be ruled out.

For Grade 4 serum creatinine elevation, Opdualag must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

For Grade 2 or 3 serum creatinine elevation, Opdualag should be withheld, and corticosteroids should be initiated at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Once creatinine levels have returned to baseline, Opdualag may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 1 to 2 mg/kg/day methylprednisolone equivalents, and Opdualag must be permanently discontinued.

Immune-Mediated Endocrinopathies

Severe endocrinopathies, including hypothyroidism, hyperthyroidism, adrenal insufficiency (including secondary adrenocortical insufficiency), hypophysitis (including hypopituitarism), and diabetes mellitus have been observed with Opdualag. Cases of diabetic ketoacidosis have been observed with nivolumab monotherapy and could potentially occur with Opdualag (see [8. Adverse Reactions](#)).

Patients should be monitored for clinical signs and symptoms of endocrinopathies, and for hyperglycaemia and changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation). Patients may present with fatigue, headache, mental status changes, abdominal pain, unusual bowel habits, and hypotension, or nonspecific symptoms which may resemble other causes such as brain metastasis or underlying disease. Unless an alternate etiology has been identified, signs or symptoms of endocrinopathies should be considered immune-mediated.

For symptomatic hypothyroidism, Opdualag should be withheld, and thyroid hormone replacement should be initiated as needed. For symptomatic hyperthyroidism, Opdualag should be withheld and

antithyroid medication should be initiated as needed. Corticosteroids at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the thyroid is suspected. Once symptoms resolve, Opdualag may be resumed after corticosteroid taper, if needed. Monitoring of thyroid function should continue to ensure appropriate hormone replacement is utilised. Opdualag must be permanently discontinued for life-threatening (Grade 4) hyperthyroidism or hypothyroidism.

Opdualag must be permanently discontinued for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. For symptomatic Grade 2 adrenal insufficiency, Opdualag should be withheld, and physiologic corticosteroid replacement should be initiated as needed. Monitoring of adrenal function and hormone levels should continue to ensure appropriate corticosteroid replacement is utilised.

Opdualag must be permanently discontinued for life-threatening (Grade 4) hypophysitis. For symptomatic Grade 2 or 3 hypophysitis, Opdualag should be withheld, and hormone replacement should be initiated as needed. Corticosteroids at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the pituitary gland is suspected. Once symptoms resolve, Opdualag may be resumed after corticosteroid taper, if needed. Monitoring of pituitary function and hormone levels should continue to ensure appropriate hormone replacement is utilised.

For symptomatic diabetes, Opdualag should be withheld, and insulin replacement should be initiated as needed. Monitoring of blood sugar should continue to ensure appropriate insulin replacement is utilised. Opdualag must be permanently discontinued for life-threatening (Grade 4) diabetes.

Immune-Mediated Skin Adverse Reactions

Severe rash has been observed with Opdualag (see [8. Adverse Reactions](#)). Opdualag should be withheld for Grade 3 rash until symptoms resolve and management with corticosteroids is complete. Opdualag should be permanently discontinued for Grade 4 rash. Severe rash should be managed with high-dose corticosteroid at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

Cases of SJS and TEN, some of them with fatal outcomes, have been reported with Opdualag (see [8.5 Post-Market Adverse Reactions](#)). Rare cases of drug rash with eosinophilia and systemic symptoms (DRESS) have been observed with nivolumab monotherapy. If symptoms or signs of SJS, TEN or DRESS are suspected, Opdualag should be withheld and the patient referred to a specialized unit for assessment and treatment. If the patient has confirmed SJS, TEN or DRESS permanent discontinuation of Opdualag treatment is recommended (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Caution should be used when considering the use of Opdualag in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents.

Immune-Mediated Myocarditis

Severe immune-mediated myocarditis has been observed with Opdualag and fatal myocarditis has been observed with nivolumab.

The diagnosis of myocarditis requires a high index of suspicion. Patients with cardiac or cardio-pulmonary symptoms should be assessed for potential myocarditis. If myocarditis is suspected, prompt initiation of a high dose of steroids (prednisone 1 to 2 mg/kg/day or methylprednisolone 1 to 2 mg/kg/day) and prompt cardiology consultation with diagnostic workup according to current clinical guidelines should be initiated. Once a diagnosis of myocarditis is established, Opdualag should be permanently discontinued as described below.

For Grade 2, 3 or 4 myocarditis, Opdualag must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisone equivalents or 2 to 4 mg/kg/day methylprednisolone equivalents for Grade 2 or Grade 3-4 myocarditis, respectively.

Immune-Mediated Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome

Cases of Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome (presenting as an overlap of either two or all three conditions), some with fatal outcome, have been reported with nivolumab in combination with relatlimab, and other immune checkpoint inhibitors. It is important to recognize overlapping symptoms; patients presenting with signs or symptoms of one condition should also be monitored and evaluated for the other two conditions. Early recognition and aggressive management are essential to address associated morbidity and risk of mortality (see [4. Dosage and Administration](#)).

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions have been reported in patients treated with Opdualag: uveitis, pancreatitis, gastritis, Guillain-Barre syndrome, myositis/rhabdomyolysis, myasthenia gravis, encephalitis, hemolytic anemia, and Vogt Koyanagi-Harada syndrome (VKH).

The following additional clinically significant immune-mediated adverse reactions have been reported with nivolumab monotherapy or nivolumab in combination with other agents: demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), myasthenic syndrome, aseptic meningitis, sarcoidosis, duodenitis, and hypoparathyroidism.

For suspected immune-mediated adverse reactions, adequate evaluation should be performed to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, Opdualag should be withheld and corticosteroids administered. Upon improvement, Opdualag may be resumed after corticosteroid taper. Opdualag must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1/PD-L1 inhibitors. Treatment with Opdualag may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with Opdualag versus the risk of possible organ rejection should be considered in these patients.

In patients treated with nivolumab before or after allogeneic HSCT, rapid-onset and severe GVHD, some with fatal outcome, have been reported. Treatment with nivolumab in combination with relatlimab may increase the risk of severe GVHD and death in patients who have had prior allogeneic HSCT, mainly in those with prior history of GVHD. The benefit of treatment with Opdualag versus the possible risk should be considered in these patients.

Infusion-Related Reactions

Opdualag can cause severe infusion-related reactions. Discontinue Opdualag in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions (see [4. Dosage and Administration](#)).

Monitoring and Laboratory Tests

Liver function tests, thyroid function tests, blood glucose and electrolytes should be monitored prior to and periodically during treatment. Patients should be closely monitored during treatment for signs and symptoms of immune-mediated adverse reactions, including but not limited to: dyspnea, hypoxia,

increased frequency of bowel movements, diarrhea, elevated transaminase and bilirubin levels, elevated creatinine levels, rash, pruritus, headache, fatigue, hypotension, mental status changes, visual disturbances, muscle pain or weakness, paresthesias.

Renal

Renal Impairment

The safety and efficacy of Opdualag have not been studied in patients with severe renal impairment (see [4. Dosage and Administration](#)).

Reproductive Health

• Fertility

Studies to evaluate the effect of nivolumab and/or relatlimab on fertility have not been performed. Thus, the effect of nivolumab and/or relatlimab on male and female fertility is unknown.

Pregnancy Testing

Pregnancy status should be verified for females of reproductive potential prior to initiating Opdualag (see [7.1.1 Pregnancy](#)).

Contraception

Advise females of reproductive potential to use effective contraception during treatment with Opdualag and for at least 5 months following the last dose of Opdualag (see [10.3 Pharmacokinetics](#)).

7.1. Special Populations

7.1.1. Pregnancy

Based on its mechanism of action and findings in animals, Opdualag can cause fetal harm when administered to a pregnant woman. Studies in animals receiving nivolumab have shown embryofetal toxicity. In animal reproduction studies, administration of nivolumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased abortion and premature infant death. Human IgG4 is known to cross the placenta and nivolumab and relatlimab are IgG4 antibodies; therefore, nivolumab and relatlimab have the potential to be transmitted from the mother to the developing fetus. There are no studies on the use of Opdualag in pregnant women to evaluate a drug-associated risk. Opdualag is not recommended during pregnancy and in women of childbearing potential not using effective contraception. Effective contraception should be used during treatment with Opdualag and for at least 5 months following the last dose of Opdualag (see [16. Non-Clinical Toxicology](#)).

Teratogenic Risk

Based on its mechanism of action, Opdualag can cause fetal harm when administered to a pregnant woman.

7.1.2. Breastfeeding

The excretion of nivolumab and relatlimab in human milk, the effects on the breastfed child, or the effects on milk production have not been studied. Because nivolumab and relatlimab may be excreted

in human milk and because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during treatment with Opdualag and for at least 5 months after the last dose.

7.1.3. Pediatrics

Use of Opdualag in pediatric patients 12 years of age or older and weighing at least 40 kg is supported by predicted drug exposures at the recommended Opdualag dose that are expected to result in similar safety and efficacy to that of adults.

The safety and efficacy of Opdualag have not been established in pediatric patients under the age of 12 years or in patients 12 years of age or older and weighing less than 40 kg.

7.1.4. Geriatrics

Of the 355 patients treated with Opdualag in RELATIVITY 047, 47% of patients were 65 years or older, and 19% of patients were 75 years or older. No overall differences in safety or effectiveness were observed between elderly patients (≥ 65 years) and younger patients (< 65 years).

8. Adverse Reactions

8.1. Adverse Reaction Overview

Unresectable or Metastatic Melanoma:

The safety of Opdualag was evaluated in RELATIVITY-047, a randomized (1:1), double-blinded trial in patients with previously untreated metastatic or unresectable melanoma (see [14. Clinical Trials](#)). Patients received intravenous Opdualag (nivolumab 480 mg and relatlimab 160 mg) every 4 weeks ($n=355$) or nivolumab 480 mg by intravenous infusion every 4 weeks ($n=359$). Patients were treated with Opdualag or nivolumab until disease progression or unacceptable toxicity (see [14. Clinical Trials](#)).

The median duration of treatment was 8.3 months (range: 0-38.8 months) for Opdualag and 6.5 months (range: 0-40.5 months) for nivolumab: 54.9% of patients in the Opdualag arm received Opdualag for ≥ 6 months and 38.0% of patients received Opdualag for ≥ 1 year. The median number of Opdualag doses received was 10 (range: 1-43 doses).

Fatal adverse reactions occurred in 4 (1.1%) patients who were treated with Opdualag; these included hemaphagocytic lymphohistiocytosis, acute edema of the lung, pneumonitis and multi-organ failure.

Serious adverse reactions occurred in 34% of patients treated with Opdualag and 28% of patients treated with nivolumab. The most common serious adverse reactions reported in $\geq 1\%$ of patients treated with Opdualag were adrenal insufficiency, anemia, myocarditis, colitis, diarrhea, pneumonia, urinary tract infection and back pain.

Adverse reactions leading to discontinuation of study therapy were reported in 19.2% of patients treated with Opdualag and in 11.7% of patients treated with nivolumab. The most common ($>1\%$) adverse reactions leading to discontinuation of Opdualag were pneumonitis and myocarditis. In the Opdualag arm, 49.3% of patients had at least one dose withheld for an adverse reaction.

The most common adverse reactions reported in $\geq 15\%$ of patients treated with Opdualag were fatigue, musculoskeletal pain, rash, pruritus, arthralgia, diarrhea, headache, nausea, hypothyroidism, cough and decreased appetite.

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Unresectable or Metastatic Melanoma:

RELATIVITY-047:

Table 4 lists adverse reactions that occurred in at least 1% of Opdualag treated patients in RELATIVITY-047 (19.9 months median follow-up).

Table 4: Adverse Reactions Reported in ≥1% of Patients in RELATIVITY-047

System Organ Class Preferred Term	Opdualag (n=355)		Nivolumab (n=359)	
	All Grade	Grades 3-4	All Grade	Grades 3-4
	Percentage (%) of Patients ¹			
Blood and Lymphatic Disorders				
Eosinophilia ²	2.5	0	1.1	0
Cardiac Disorders				
Myocarditis	1.4	0.6	0.6	0
Endocrine Disorders				
Hypothyroidism ³	16.3	0	12.8	0
Hyperthyroidism	6.5	0	7.8	0
Adrenal insufficiency	4.5	1.4	1.1	0
Thyroiditis ⁴	2.5	0	1.7	0
Hypophysitis	1.4	0.6	0.8	0.3
Eye Disorders				
Uveitis ⁵	1.4	0	1.1	0
Visual impairment	1.7	0	0.3	0
Dry eye ⁶	2.0	0	1.4	0
Increased lacrimation	1.4	0	0.6	0
Gastrointestinal Disorders				
Diarrhea	25.6	1.7	18.7	1.4
Nausea	19.4	0.6	15.0	0
Abdominal pain ⁷	13.5	0.3	12.5	0.8

Constipation	11.3	0.6	6.4	0
Vomiting	10.1	0.6	6.4	0.3
Dry mouth	8.5	0	5.0	0
Colitis	3.1	1.1	0.6	0
Stomatitis ⁸	2.8	0	1.7	0
Gastritis	2.5	0.8	1.1	0.3
Dysphagia	2.0	0	1.1	0
Pancreatitis ⁹	1.4	0	0.6	0
General Disorders and Administration Site Conditions				
Fatigue ¹⁰	40.8	2.0	30.1	0.6
Pyrexia ¹¹	12.1	0	10.0	0.3
Edema ¹²	8.7	0.3	5.8	0.3
Influenza like illness	5.4	0	4.5	0
Chills	3.7	0	3.9	0
Hepatobiliary Disorders				
Hepatitis ¹³	1.1	1.1	1.1	0.6
Infections and infestations				
Urinary tract infection	11.3	1.1	8.9	0.6
Upper respiratory tract infection ¹⁴	9.3	0	9.7	0.3
Injury, poisoning and procedural complications				
Infusion-related reaction	6.2	0	3.6	0.3
Investigations				
Weight decreased	8.5	1.4	3.6	0
Metabolism and nutrition disorders				
Decreased appetite	15.5	0.6	7.5	0.3
Hyperuricemia	3.4	0	1.1	0
Hypoalbuminemia ¹⁵	2.0	0	2.2	0
Diabetes mellitus ¹⁶	1.1	0.6	1.4	0.8
Dehydration	1.1	0.6	0.8	0.3
Musculoskeletal and Connective Tissue Disorders				

Musculoskeletal pain ¹⁷	32.1	2.3	22.3	1.1
Arthralgia	25.6	1.7	17.3	0.6
Arthritis ¹⁸	5.6	0.8	1.1	0.3
Muscle spasms ¹⁹	2.8	0	1.1	0
Muscular weakness	2.8	0.3	2.2	0.8
Nervous System Disorders				
Headache	19.7	0.3	12.0	0.3
Dizziness ²⁰	9.9	0	8.4	0
Peripheral neuropathy ²¹	6.2	0	2.8	0.6
Dysgeusia	2.0	0	0.3	0
Psychiatric disorders				
Confusional state ²²	1.7	0.6	0.3	0
Renal and Urinary Disorders				
Renal failure ²³	2.0	1.1	1.7	0.3
Proteinuria	1.4	0	0.8	0
Respiratory, Thoracic, and Mediastinal Disorders				
Cough ²⁴	15.8	0.3	12.0	0
Dyspnea ²⁵	10.4	1.4	6.7	0.3
Pneumonitis ²⁶	5.1	0.8	2.8	0.3
Nasal congestion	2.8	0	1.1	0
Skin and Subcutaneous Tissue Disorders				
Rash ²⁷	28.7	1.7	21.2	1.4
Pruritus	26.2	0	17.8	0.6
Vitiligo	13.2	0	12.0	0
Dry skin	3.9	0	2.5	0
Alopecia	1.7	0	0.8	0
Lichenoid keratosis	1.1	0	0.3	0
Photosensitivity reaction	1.4	0	0.3	0
Vascular Disorders				
Phlebitis	1.1	0	0.3	0

1. Incidences presented in this table are based on reports of treatment-emergent adverse events.

2. Includes eosinophilia, eosinophilia count increased.

3. Includes hypothyroidism, autoimmune hypothyroidism.
4. Includes thyroiditis, autoimmune thyroiditis.
5. Includes uveitis, iridocyclitis.
6. Includes dry eye, xerophthalmia.
7. Includes abdominal pain, abdominal discomfort, abdominal pain lower, abdominal pain upper, abdominal tenderness.
8. Includes stomatitis, aphthous ulcer, mouth ulceration, mucosal inflammation.
9. Includes pancreatitis, autoimmune pancreatitis, pancreatitis acute, pancreatitis chronic.
10. Includes fatigue, asthenia.
11. Includes pyrexia, body temperature increased, tumor associated fever.
12. Includes edema, generalised edema, peripheral edema, and peripheral swelling.
13. Includes hepatitis, autoimmune hepatitis, hepatitis toxic.
14. Includes upper respiratory tract infection, nasopharyngitis, pharyngitis, rhinitis.
15. Includes hypoalbuminaemia, blood albumin decreased.
16. Includes diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus.
17. Includes musculoskeletal pain, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, spinal pain.
18. Includes arthritis, autoimmune arthritis, osteoarthritis, seronegative arthritis.
19. Includes muscle spasm, muscle contractions.
20. Includes dizziness, vertigo.
21. Includes peripheral neuropathy, dysaesthesia, hyperaesthesia, hypoaesthesia, peripheral motor neuropathy, peripheral sensorimotor neuropathy, peripheral sensory neuropathy.
22. Includes confusional state, apathy.
23. Includes renal failure, acute kidney injury.
24. Includes cough, productive cough.
25. Includes dyspnea, dyspnea exertional.
26. Includes pneumonitis, interstitial lung disease.
27. Includes rash, pustular rash, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, dermatitis psoriasiform, drug eruption, rash erythematous, rash macular, rash maculo-papular, rash morbilliform, rash papular, rash pruritic, rash vesicular.

Description of Immune-Mediated Adverse Reactions:

The management guidelines for these adverse reactions are described in Table 2 (see [4. Dosage and Administration](#) and [7. Warnings and Precautions](#)).

Immune-Mediated Pulmonary Adverse Reactions:

In patients treated with Opdualag in melanoma, the incidence of pneumonitis, including interstitial lung disease and lung infiltration was 5.1% (18/355). Grade 3 and 4 events were reported in 0.8% (3/355) of patients. A fatal adverse reaction of pneumonitis was reported in a patient treated with Opdualag.

The median time to onset was 28 weeks (range: 3.6-94.4). Six patients (1.7%) required permanent discontinuation of Opdualag. Ten patients (55.6%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 15 patients (83.3%) with a median time to resolution of 12.0 weeks (range: 2.1-29.7+); + denotes a censored observation.

Immune-Mediated Gastrointestinal Adverse Reactions:

In patients treated with Opdualag in melanoma, the incidence of diarrhea, colitis, or frequent bowel movements was 15.8% (56/355). Grade 3 and 4 events were reported in 2.0% (7/355) of patients.

The median time to onset was 14 weeks (range: 0.1-95.6). Seven patients (2.0%) required permanent discontinuation. Nineteen patients (33.9%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 51 patients (92.7%) with a median time to resolution of 3.9 weeks (range: 0.1-136.9+).

Immune-Mediated Hepatic Adverse Reactions:

In patients treated with Opdualag in melanoma, the incidence of hepatitis and liver function test abnormalities was 13.2% (47/355). Grade 3 and 4 events were reported in 3.9% (14/355) of patients.

The median time to onset was 11 weeks (range: 2.0-144.9). Seven patients (2.0%) required permanent discontinuation. Eighteen patients (38.3%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 37 patients (78.7%) with a median time to resolution of 6.1 weeks (range: 1.0-88.1+).

Immune-Mediated Renal Adverse Reactions:

In patients treated with Opdualag in melanoma, the incidence of nephritis or renal dysfunction was 4.5% (16/355). Grade 3 and 4 events were reported in 1.4% (5/355) of patients.

The median time to onset was 21 weeks (range: 1.9-127.9). Four patients (1.1%) required permanent discontinuation. Four patients (25.0%) received high dose corticosteroids (40 mg prednisone or equivalents). Resolution occurred in 13 patients (81.3%) with a median time to resolution of 8.1 weeks (range: 0.9-91.6+).

Immune-Mediated Endocrinopathies:

In patients treated with Opdualag in melanoma, the incidence of endocrinopathies was 26.5% (94/355). Thyroid disorders, including hypothyroidism and hyperthyroidism, occurred in 20.8% (74/255) of patients. There were no incidences of Grade 3 and 4 thyroid disorders. Adrenal insufficiency (including adrenocortical insufficiency acute) occurred in 4.8% (17/355) of patients. Grade 3 and 4 events of adrenal insufficiency occurred in 1.4% (5/355) of patients. Pituitary disorders, including hypophysitis occurred in 2.5% (9/355) of patients. One patient (0.3%) experienced a Grade 3-4 event of hypophysitis. Diabetes mellitus (including Type 1 diabetes mellitus) occurred in 0.3% of patients. Incidences of Grade 3 and 4 diabetes mellitus were in one patient (0.3%), which was a Grade 3-4 event.

The median time to onset of these endocrinopathies was 13 weeks (range: 1.0-73.0). Four patients (1.1%) required permanent discontinuation. Seven patients (7.4%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 26 patients (27.7%) with a time to resolution range from 0.4 to 176.0+ weeks.

Immune-Mediated Skin Adverse Reactions:

In patients treated with Opdualag in melanoma, the incidence of rash, including pruritis and vitiligo was 45.1% (160/355). Grade 3 and 4 events were reported in 1.4% (5/355) of patients.

The median time to onset was 8 weeks (range: 0.1-116.4). One patient (0.3%) required permanent discontinuation. Six patients (3.8%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 76 patients (47.5%) with a median time to resolution of 64.1 weeks (range: 0.1-166.9+).

Immune-Mediated Myocarditis:

In patients treated with Opdualag in melanoma, the incidence of myocarditis was 1.4% (5/355). Incidences of Grade 3 and 4 events were 0.6 % (2/355).

The median time to onset was 4.1 weeks (range: 2.1-6.3). Five patients (1.4%) required permanent discontinuation. Five patients (100%) received high dose corticosteroids (at least 40 mg prednisone or equivalents). Resolution occurred in 5 patients (100%) with a median time to resolution of 3 weeks (1.9-14.0).

Infusion Reactions:

In patients treated with Opdualag, the incidence of hypersensitivity/infusion reactions was 6.8% (24/355). All events were Grade 1 or 2.

8.2.1. Clinical Trial Adverse Reactions – Pediatrics

No pediatric patients were enrolled in RELATIVITY-047.

The safety and efficacy of Opdualag for the treatment of unresectable or metastatic melanoma have been established in pediatric patients 12 years or older who weigh at least 40 kg, based on population PK analysis (see [10.3 Pharmacokinetics](#)).

The safety and efficacy of Opdualag in pediatric patients younger than 12 years of age or 12 years of age or older and weighing less than 40 kg have not been established (see [1.1 Pediatrics](#), [4.1 Dosing Considerations](#), [7.1.3 Pediatrics](#)).

8.3. Less Common Clinical Trial Adverse Reactions

Table 5: Less Common Clinical Trial Adverse Reactions (<1%)

OPDIVO Study	System Organ Class
Unresectable or Metastatic Melanoma: (previously untreated) RELATIVITY-047	<u>Blood and lymphatic system disorders</u> : hemolytic anemia
	<u>Cardiac disorders</u> : pericardial effusion
	<u>Endocrine disorders</u> : hypopituitarism, hypogonadism
	<u>Eye disorders</u> : Vogt-Koyanagi-Harada disease, ocular hyperaemia
	<u>Gastrointestinal disorders</u> : esophagitis
	<u>Hepatobiliary disorders</u> : cholangitis
	<u>Infections and Infestations</u> : folliculitis
	<u>Investigations</u> : c-reactive protein increased, red blood cell sedimentation rate increased
	<u>Musculoskeletal and connective tissue disorders</u> : myositis, Sjogren's Syndrome, polymyalgia rheumatica, rheumatoid arthritis, systemic lupus erythematosus
	<u>Nervous system disorders</u> : encephalitis, Guillain-Barré syndrome, optic neuritis
	<u>Renal and urinary disorders</u> : nephritis
	<u>Reproductive system and breast disorders</u> : azoopermia
	<u>Respiratory, thoracic and mediastinal disorders</u> : asthma
	<u>Skin and subcutaneous tissue disorders</u> : pemphigoid, psoriasis, urticaria

8.3.1. Less Common Clinical Trial Adverse Reactions – Pediatrics

No pediatric patients were enrolled in RELATIVITY-047.

8.4. Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data

Clinical Trial Findings

The incidence of worsening laboratory abnormalities, reported in RELATIVITY-047 is shown in Table 6.

Table 6: Laboratory Abnormalities Worsening from Baseline Occurring in ≥10% of Patients with Unresectable or Metastatic Melanoma treated with Opdualag (RELATIVITY-047)

Laboratory Abnormalities	Percentage of Patients with Worsening Laboratory Test from Baseline ¹			
	Opdualag		Nivolumab	
	Grades 1-4 n (%)	Grades 3-4 n (%)	Grades 1-4 n (%)	Grades 3-4 n (%)
Chemistry				
Increased AST	116 (33.8)	10 (2.9)	85 (24.6)	5 (1.4)
Increased ALT	101 (29.4)	12 (3.5)	97 (28.1)	8 (2.3)
Hyponatremia	92 (27.0)	5 (1.5)	80 (23.2)	4 (1.2)
Hyperkalemia	56 (16.4)	6 (1.8)	61 (17.7)	3 (0.9)
Hypocalcemia	57 (17.0)	2 (0.6)	51 (15.2)	1 (0.3)
Hypomagnesemia	52 (15.6)	2 (0.6)	47 (13.7)	0
Increased alkaline phosphatase	75 (22.1)	2 (0.6)	58 (16.8)	2 (0.6)
Increased creatinine	82 (24.0)	5 (1.5)	65 (18.8)	3 (0.9)
Hypercalcemia	39 (11.6)	3 (0.9)	46 (13.7)	3 (0.9)
Hypokalemia	35 (10.3)	1 (0.3)	36 (10.4)	1 (0.3)
Hematology				
Anemia	139 (41.1)	12 (3.6)	119 (34.7)	12 (3.5)
Lymphopenia	118 (35.2)	11 (3.3)	105 (30.7)	11 (3.2)
Neutropenia	45 (13.4)	0	34 (9.9)	1 (0.3)
Leukopenia	44 (13.0)	0	49 (14.3)	0

1. Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: Opdualag group (range: 35 to 343 patients) and nivolumab group (range: 70 to 345 patients).

8.5. Post-Market Adverse Reactions

The following events have been identified during post-approval use of nivolumab in combination with relatlimab. Because reports are voluntary from a population of unknown size, an estimate of frequency cannot be made.

Nervous system disorders: myasthenia gravis, Myocarditis-Myositis-Myasthenia Gravis Overlap

Syndrome.

Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).

9. Drug Interactions

9.2. Drug Interactions Overview

There have been no formal drug interaction studies performed with Opdualag in humans. Nivolumab and relatlimab are both monoclonal antibodies and as such, are not metabolized by cytochrome P450 (CYP) enzymes or other drug metabolizing enzymes; therefore, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of nivolumab or relatlimab.

9.3. Drug-Behaviour Interactions

Drug-behavioural interactions have not been established.

9.4. Drug-Drug Interactions

Systemic immunosuppression

The use of systemic corticosteroids and other immunosuppressants at baseline, before starting Opdualag, should be avoided because of their potential interference with the pharmacodynamic activity. However, systemic corticosteroids and other immunosuppressants can be used after starting Opdualag to treat immune-mediated adverse reactions.

9.5. Drug-Food Interactions

Interactions with food have not been established.

9.6. Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10. Clinical Pharmacology

10.1. Mechanism of Action

Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Relatlimab is a human IgG4 monoclonal antibody that binds to the LAG-3 T cell receptor, blocks its interaction with ligands, including MHC II, and reduces LAG-3 pathway-mediated inhibition of the immune response. Antagonism of this pathway promotes T-cell proliferation and cytokine secretion.

The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone. In murine syngeneic tumor models, LAG-3 blockade potentiates the anti-tumor activity of PD-1 blockage, inhibiting tumor growth and promoting tumor regression.

10.2. Pharmacodynamics

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of Opdualag have not been fully characterized.

10.3. Pharmacokinetics

The pharmacokinetics (PK) of relatlimab following the administration of Opdualag was characterized in patients with various cancers who received relatlimab doses of 20 to 800 mg every 2 weeks and 160 to 1440 mg every 4 weeks either as a monotherapy or in combination with nivolumab doses of 80 or 240 mg every 2 weeks or 480 mg every 4 weeks.

Steady-state concentrations of relatlimab were reached by 16 weeks with an every 4-week regimen and the systemic accumulation was 1.9-fold. The average concentration (C_{avg}) of relatlimab after the first dose increased dose proportionally at doses ≥ 160 mg every 4 weeks.

The nivolumab and relatlimab pharmacokinetic parameters are summarized for adults in Table 7.

Table 7: Geometric Mean (CV%) of Nivolumab and Relatlimab Steady-state Exposures Following 480 mg Nivolumab and 160 mg Relatlimab Fixed Dose Combination Every 4 Weeks

	C_{max} ($\mu\text{g/mL}$)	C_{min} ($\mu\text{g/mL}$)	C_{avg} ($\mu\text{g/mL}$)
Nivolumab	187 (32.9%)	59.7 (58.6%)	94.4 (43.3%)
Relatlimab	62.2 (30.1%)	15.3 (64.3%)	28.8 (44.8%)

Based on population PK analyses, the Opdualag fixed-dose combination infusion duration of 30 minutes and 60 minutes were predicted to produce similar (<1% different) exposures of nivolumab and relatlimab.

In RELATIVITY-047, the nivolumab geometric mean C_{min} at steady state in the Opdualag arm was similar to the nivolumab arm with a geometric mean ratio of 0.931 (95% CI: 0.855-1.013).

Distribution

The geometric mean value (CV%) for nivolumab volume of distribution at steady state is 6.65 L (19.2%) and relatlimab is 6.65 L (19.8%).

Metabolism

Nivolumab and relatlimab are therapeutic IgG4 mAb that are expected to be catabolised into small peptides, amino acids, and small carbohydrates by lysosome or receptor-mediated endocytosis.

Elimination

Nivolumab clearance is 21.1% lower [geometric mean (CV%), 7.57 mL/h (40%)] at steady state than that after the first dose [9.59 mL/h (40.3%)] and the terminal half-life ($t_{1/2}$) is 26.5 days (36.4%).

Relatlimab clearance is 9.7% lower [geometric mean (CV%), 5.48 mL/h (41.3%)] at steady state than that after the first dose [6.06 mL/h (38.9%)]. Following Opdualag (nivolumab 480 mg and relatlimab 160 mg administered every four weeks), the geometric mean (CV%) effective half-life ($t_{1/2}$) of relatlimab is 26.2 days (37%).

Special populations and conditions

- A population PK analysis suggested that the following factors had no clinically important effect on the clearance of nivolumab and relatlimab: age (range: 17-92 years), sex, or race (Caucasian, Asian, and Black/African American). The body weight (range: 37-170 kg) was a significant covariate on the nivolumab and relatlimab PK; however, there is no clinically relevant impact based on exposure-response analysis.

- **Pediatrics**

Use of Opdualag is supported by evidence from an adequate and well-controlled study in adults and additional data analyses that suggest that nivolumab and relatlimab exposures in pediatric patients 12 years of age who weigh at least 40 kg are expected to result in similar safety and efficacy to that of adults. The pharmacokinetics of monoclonal antibodies and the course of unresectable or metastatic melanoma are sufficiently similar in adults and pediatric patients 12 years of age or older to allow extrapolation of data from adult patients to pediatric patients 12 years of age or older (who weigh at least 40 kg). The safety and efficacy of Opdualag in pediatrics <12 years of age, and pediatric patients 12 years of age or older who weigh less than 40 kg has not been established.

Nivolumab clearance and volume of distribution in pediatric patients with solid tumors were 36% and 16% lower, respectively, than those of adult reference patients. Relatlimab clearance and volume of distribution are also expected to be lower in adolescents than adults, since both therapies are IgG4 mAbs. However, no clinically meaningful differences in the exposure of nivolumab and relatlimab are expected between adults and pediatric patients 12 years of age or older and weighing at least 40 kg, at the same recommended dose.

- **Hepatic Insufficiency**

In a population PK analysis, it was observed that mild hepatic impairment (total bilirubin [TB] less than or equal to upper limit of normal [ULN] and AST greater than ULN or TB greater than 1 to 1.5 times ULN and any AST) or moderate hepatic impairment (TB greater than 1.5 to 3 times ULN and any AST) had no clinically important effect on the clearance of nivolumab and relatlimab. The impact of severe hepatic impairment on the pharmacokinetics of nivolumab and relatlimab is unknown (see [7. Warnings and Precautions](#)).

- **Renal Insufficiency**

In a population PK analysis, it was observed that mild or moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²) had no clinically important effect on the clearance of nivolumab and

relatlimab. The impact of severe renal impairment on the pharmacokinetics of nivolumab and relatlimab is unknown (see [7. Warnings and Precautions](#)).

10.4. Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity with Opdualag.

The incidence of treatment-emergent anti-nivolumab antibodies and neutralizing antibodies against nivolumab in the Opdualag group were 3.8% (11/288) and 0.3% (1/288), respectively, which were similar to that observed in the nivolumab group: 5.9% (16/272) and 0.4% (1/272), respectively.

In RELATIVITY-047, the incidence of treatment-emergent anti-relatlimab antibodies and neutralizing antibodies against relatlimab in the Opdualag group was 5.6% (16/286) and 0.3% (1/286), respectively.

Due to the low incidence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, safety, or efficacy of Opdualag is unknown.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Opdualag and nivolumab with the incidence of antibodies in other studies or to other products may be misleading.

11. Storage, Stability, and Disposal

Opdualag (nivolumab and relatlimab) for intravenous use is supplied in a single-use vial containing 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL) per carton.

Store Opdualag under refrigeration at 2°C to 8°C. Protect Opdualag in the original carton to protect from light until time of use. Do not freeze or shake.

Part 2: Scientific Information

13. Pharmaceutical Information

Drug Substance

Non-proprietary name of the drug substance(s): nivolumab and relatlimab.

Molecular formula and molecular mass:

The predominant molecular isoform of nivolumab has a molecular formula of $C_{6462}H_{9990}N_{1714}O_{2074}S_{42}$ (with heavy chain N-terminal pyroglutamate, without C-terminal lysine and with G0F/G0F glycoform) with a calculated molecular weight of 146,221 Da.

The predominant molecular isoform of relatlimab has a molecular formula of $C_{6584}H_{10106}N_{1718}O_{2102}S_{38}$ (with heavy chain N-terminal pyroglutamate, without C-terminal lysine and with G0F/G0F glycoform) with a calculated molecular weight of 148,178 Da.

Structure:

Nivolumab is a fully human monoclonal antibody of the IgG4 class consisting of four polypeptide chains: two identical heavy chains of 440 amino acids and two identical kappa light chains of 214 amino acids, which are linked through inter-chain disulfide bonds.

Relatlimab is a human monoclonal antibody of the immunoglobulin G4 (IgG4) class consisting of four polypeptide chains: two identical heavy chains and two identical light chains of amino acids that are directed against human lymphocyte activation gene 3 (LAG-3).

Physicochemical properties:

OPDUALAG is a sterile, preservative-free, non-pyrogenic, clear to opalescent, colorless to slightly yellow liquid for intravenous infusion that is free of particles.

The solution has a pH of approximately 5.8 and an osmolality of approximately 310 mOsm/kg.

Product Characteristics:

Nivolumab, anti-programmed death receptor-1 (anti-PD-1) and relatlimab, anti-lymphocyte activation gene-3 (anti-LAG-3) are human IgG4 monoclonal antibodies that specifically block PD-1 and LAG 3, respectively. Both nivolumab and relatlimab are produced in Chinese Hamster Ovary cells by recombinant DNA technology.

14. Clinical Trials

Table 8: Summary of Opdualag Clinical Trials

Indication	Trial
Unresectable or metastatic melanoma	RELATIVITY-047 (First-line)

14.1. Clinical Trials by Indication

Unresectable or Metastatic Melanoma

Controlled Trial in Melanoma Patients Previously Untreated: RELATIVITY-047

RELATIVITY-047 is a phase 2/3, randomized (1:1), double-blinded trial in 714 patients with previously untreated metastatic or unresectable Stage III or IV melanoma. Patients were allowed to have received prior adjuvant or neoadjuvant melanoma therapy: anti-PD-1 therapy, anti-CTLA-4 therapy, or BRAF-MEK inhibitors were allowed if there was at least 6 months between the last dose of therapy and date of recurrence; interferon therapy was allowed if the last dose was at least 6 weeks prior to randomization.

The trial excluded patients with active autoimmune disease, a history of myocarditis, medical conditions requiring systemic treatment with moderate or high dose corticosteroids or immunosuppressive medicines, uveal melanoma, active or untreated brain or leptomeningeal metastases, elevated troponin levels >2 times ULN, and ECOG performance status score ≥ 2 . Patients were randomized to receive Opdualag (480 mg nivolumab and 160 mg relatlimab) by intravenous infusion every 4 weeks (n=355) or nivolumab 480 mg by intravenous infusion every 4 weeks (n=359) until disease progression or unacceptable toxicity.

Randomization was stratified by tumor PD-L1 expression ($\geq 1\%$ vs. $<1\%$) using PD-L1 IHC 28-8 pharmDx test, LAG-3 expression ($\geq 1\%$ vs. $<1\%$) as determined by an analytically validated LAG-3 IHC clinical trial assay, BRAF V600 mutation status (V600 mutation positive vs. wild type), and M stage per the American Joint Committee on Cancer (AJCC) version 8 staging system (M0/M1any [0] vs. M1 any [1]).

The primary efficacy outcome measure was progression-free survival (PFS) determined by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The secondary efficacy outcome measures were overall survival (OS) and objective response rate (ORR) determined by BICR using RECIST v1.1. Tumor assessments were conducted 12 weeks after randomization and continued every 8 weeks up to week 52 and then every 12 weeks.

The median age of the trial population was 63 years (range: 20 to 94) with 47% ≥ 65 years of age and 19% ≥ 75 years of age. The majority were male (58%), and White (97%). Baseline ECOG performance score was 0 (67%) or 1 (33%). Disease characteristics were: PD-L1 expression $\geq 1\%$ (41%); LAG-3 expression $\geq 1\%$ (75%); AJCC Stage IV disease (92%); M1c disease (39%), M1d disease (2.4%); elevated LDH (36%); and BRAF V600 mutation-positive melanoma (39%).

At the primary PFS analysis, with a median follow-up of 13.2 months, a statistically significant improvement in PFS was demonstrated for patients randomized to the Opdualag arm compared with the nivolumab arm. The result of the final OS analysis, with a median follow-up of 19.9 months, was not statistically significant.

Efficacy results are presented in Table 9 and Figure 1.


Table 9: Efficacy Results - RELATIVITY-047

	Opdualag (n=355)	Nivolumab (n=359)
Progression-free Survival^{1,2}		

Disease progression or death (%)	180 (50.7)	211 (58.8)
Median in months ³ (95% CI)	10.1 (6.4, 15.7)	4.6 (3.4, 5.6)
Hazard ratio ⁴ (95% CI)	0.75 (0.62, 0.92)	
p-value ⁵	0.0055	
Overall Survival⁶		
Deaths (%)	137 (39)	160 (45)
Median in months ³ (95% CI)	NR (34.2, NR)	34.1 (25.2, NR)
Hazard ratio ⁴ (95% CI)	0.80 (0.64, 1.01)	
p-value ⁵	NS ⁷	
Objective Response Rate^{1,6,8} n (%) (95% CI)	153 (43) (38, 48)	117 (33) (28, 38)
Complete response, n (%)	58 (16)	51 (14)
Partial response, n (%)	95 (27)	66 (18)

1. Assessed by BICR.
2. Final PFS analysis, with a median follow-up of 13.2 months.
3. Kaplan-Meier estimate.
4. Based on stratified Cox proportional hazard model.
5. Based on stratified log-rank test.
6. At the time of the final OS analysis, which was event-driven and occurred after the final PFS analysis, with a median follow-up of 19.9 months.
7. Not Significant at alpha level 0.04302.
8. Not formally tested based on the testing hierarchy.

Abbreviation: CI=confidence interval, NR=not reached, NS=not significant



Number of Subjects at Risk

OPDUALAG

355 201 163 132 99 81 75 67 30 6

Nivolumab

359 174 124 94 72 61 57 49 27 6

Figure 1: Progression-free Survival - RELATIVITY-047

In an exploratory PFS analysis for the subgroups defined by the stratification factor of PD-L1 status ($\geq 1\%$ vs. $< 1\%$), the HRs were 0.95 (95% CI: 0.68, 1.33) and 0.66 (95% CI: 0.51, 0.84), respectively.

16. Non-Clinical Toxicology

Opdualag contains nivolumab and relatlimab.

General Toxicology:

No animal studies were conducted with nivolumab in combination with relatlimab to evaluate potential carcinogenicity, genotoxicity or reproductive and developmental toxicity.

Inhibition of PD-1 and LAG-3 results in autoimmunity in preclinical models. Mice deficient in both PD-1 and LAG-3 develop lethal systemic autoimmunity that includes myocarditis.

In a 1-month study in monkeys, 1 male animal that received nivolumab and relatlimab had inflammation within the central nervous system (choroid plexus, vasculature, meninges, spinal cord) and the reproductive tract (epididymis, seminal vesicles and testes) that was associated with clinical

signs necessitating euthanasia. CNS inflammation was observed in other monkeys; however, there were no associated clinical signs. Although safety margins were not established for these effects with the combination, they occurred at doses that suppose exposure levels significantly higher than those reached in patients (13-fold higher for nivolumab and 97-fold higher for relatlimab).

Carcinogenicity: No long-term animal studies were conducted to assess the carcinogenic potential of nivolumab or relatlimab.

Genotoxicity: No studies were conducted to assess the genotoxic potential of nivolumab or relatlimab.

Reproductive and Developmental Toxicology: Fertility studies have not been performed with nivolumab or relatlimab. In 1-month and 3-month repeat-dose toxicology studies with nivolumab, there were no notable effects in the reproductive organs of monkeys; however, most animals in these studies were not sexually mature. In the 3-month repeat-dose toxicology study with relatlimab, wherein most monkeys were sexually mature, there were no notable effects in the male and female reproductive organs. In the 1-month combination study with nivolumab and relatlimab, in which most monkeys were not sexually mature, inflammation of the reproductive tract was observed in one male monkey.

Nivolumab:

One function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining immune tolerance to the fetus. The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab twice weekly from the onset of organogenesis through delivery, at exposure levels of between 9 and 42 times higher than those observed at the clinical dose of 3 mg/kg (based on AUC). Nivolumab administration resulted in a non-dose-related increase in spontaneous abortion and increased neonatal death in the absence of maternal toxicity. In surviving infants (18 of 32 compared to 11 of 16 vehicle-exposed infants) of cynomolgus monkeys treated with nivolumab, there were no apparent malformations and no effects on neurobehavioral, immunological, or clinical pathology parameters throughout the 6-month postnatal period.

Relatlimab:

There are no available animal data on the effect of relatlimab on pregnancy and reproduction. However, the effects of murine anti-LAG-3 antibodies were evaluated in mice using syngeneic and allogeneic breeding models. No maternal or developmental effects were observed; however, based on the mechanism of action, inhibition of LAG-3 with relatlimab can have a similar negative effect as nivolumab on pregnancy.

Special Toxicology: In animal models, inhibition of PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. *M. tuberculosis*-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 knockout mice have also shown decreased survival following infection with lymphocytic choriomeningitis virus.

Juvenile Toxicity: No studies have been performed to assess the potential long-term effects of early life exposure to nivolumab or relatlimab.

17. Supporting Product Monographs

1. OPDIVO, (Intravenous Infusion, 10 mg nivolumab/mL), control 305784, product monograph, Bristol-Myers Squibb Canada. (2026-06-16)

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr**OPDUALAG**[®]

(op-DEW-uh-lag)

nivolumab and relatlimab for injection

This Patient Medication Information is written for the person who will be taking **OPDUALAG**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **Opdualag**, talk to a healthcare professional.

Serious warnings and precautions box

Opdualag acts on your immune system and may cause inflammation in parts of your body. Inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

Opdualag can cause serious side effects in parts of your body which can lead to death. These serious side effects may include: inflammation of the lungs (pneumonitis), acute lung swelling caused by too much fluid trapped (edema) and a rare disease in which your immune system makes too many of otherwise normal infection fighting cells called histiocytes and lymphocytes (Haemophagocytic lymphohistiocytosis). These are not all of the possible serious or life-threatening side effects you may experience with Opdualag (see “*Serious side effects and what to do about them*”).

These side effects are most likely to begin during treatment; however, side effects can show up months after your last infusion. It is important to tell your healthcare professional immediately if you have, or develop, any of the symptoms listed under the section “*Possible side effects from using Opdualag and Serious Side Effects and What to do About Them.*”

If you are given Opdualag, it is important that you also read the package leaflet of Opdivo (nivolumab) since it is a component of Opdualag, and serious and life-threatening side effects have been observed with nivolumab.

What Opdualag is used for:

Opdualag is a medicine used to treat melanoma (a type of skin cancer) that has spread to other parts of the body or that cannot be removed with surgery, in adults and in children who are at least 12 years of age.

How Opdualag works:

Opdualag contains two active substances: nivolumab and relatlimab, which are monoclonal antibodies. They are designed to recognise and attach to a specific target substance in the body.

Nivolumab attaches to a target protein called programmed death-1 receptor (PD-1). Relatlimab attaches to a target protein called lymphocyte activation gene-3 (LAG-3). Those proteins can switch off the activity of T cells (a type of white blood cell that forms part of the immune system, the body's natural defences). By attaching to PD-1 and LAG-3, nivolumab and relatlimab block the actions of these two proteins and prevent them from switching off your T cells. This helps increase the T cell activity against the melanoma cancer cells.

The ingredients in Opdualag are:

Medicinal ingredient(s): nivolumab and relatlimab.

Non-medicinal ingredients: histidine, histidine hydrochloride monohydrate, pentetic acid, polysorbate 80, sucrose and water for injection.

Opdualag comes in the following dosage form(s):

One vial of 20 mL contains 240 mg of nivolumab and 80 mg of relatlimab. Each mL of concentrate for solution for infusion (sterile concentrate) contains 12 mg of nivolumab and 4 mg of relatlimab.

Opdualag is a clear to opalescent, colourless to slightly yellow liquid that is essentially free of particles.

It is available in cartons containing one glass vial.

Do not use Opdualag if:

- you are allergic to nivolumab, relatlimab or any of the other ingredients of this medicine. Talk to your healthcare professional if you are not sure.
- you are younger than 12 years of age or you are 12 years of age or older and weigh less than 40 kg.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Opdualag. Talk about any health conditions or problems you may have, including if you :

- **have problems with your lungs** such as breathing difficulties or cough. These may be signs of inflammation of the lungs (pneumonitis or interstitial lung disease);
- **have diarrhea** (watery, loose or soft stools) or any symptoms of **inflammation of the intestines** (colitis), such as stomach pain and mucus or blood in stool;
- **have inflammation of the liver (hepatitis)**. Signs and symptoms of hepatitis may include abnormal liver function tests, eye or skin yellowing (jaundice), pain on the right side of your stomach area, or tiredness;
- **have inflammation or problems with your kidneys**. Signs and symptoms may include abnormal kidney function tests, or decreased volume of urine;
- **have problems with your hormone producing glands** (including the pituitary, the thyroid and adrenal glands) that may affect how these glands work. Signs and symptoms that these glands are not working properly may include fatigue (extreme tiredness), weight change or headache and visual disturbances;

- **have diabetes** including a serious, sometimes life-threatening problem due to acid in the blood produced from diabetes (**diabetic ketoacidosis**); symptoms may include feeling more hungry or thirsty than usual, need to urinate more often, weight loss, feeling tired or having difficulty thinking clearly, breath that smells sweet or fruity, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat, feeling sick or being sick, stomach pain, and deep or fast breathing;
- **have inflammation of the skin** that can lead to severe skin reactions (known as toxic epidermal necrolysis and Stevens-Johnson syndrome). Signs and symptoms of severe skin reactions may include rash, itching, blistering and peeling of the skin (possibly fatal);
- **have inflammation of the heart muscle (myocarditis)**. Signs and symptoms may include chest pain, irregular and/or rapid heartbeat, fatigue, swelling in the ankles or shortness of breath;
- **have inflammation of the muscles (myositis)** that may cause muscle or joint pain, stiffness or weakness;
- **have myasthenia gravis or myasthenia syndrome**, a condition in which muscles become weak and tire easily;
- **have Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome**. An overlap of either two or three conditions;
- **have solid organ transplant rejection**;
- **have haemophagocytic lymphohistiocytosis**. A rare disease in which your immune system makes too many of otherwise normal infection fighting cells called histiocytes and lymphocytes. Symptoms may include enlarged liver and/or spleen, skin rash, lymph node enlargement, breathing problems, easy bruising, kidney abnormalities, and heart problems;
- **have graft-versus-host disease** after blood stem cell transplantation (where the transplanted cells from a donor attack your own cells). If you have received one of these transplants, your healthcare professional will consider whether you should receive treatment with Opdualag. Graft-versus-host disease can be severe and can lead to death;
- **have infusion reactions** which may include shortness of breath, itching or rash, dizziness or fever.

Tell your healthcare professional immediately if you have any of these signs or symptoms or if they get worse. **Do not try to treat your symptoms with other medicines on your own.** Your healthcare professional may:

- give you other medicines in order to prevent complications and reduce your symptoms,
- withhold the next dose of Opdualag, or
- stop your treatment with Opdualag altogether.

Please note that these signs and symptoms are **sometimes delayed** and may develop weeks or months after your last dose. Before treatment, your healthcare professional will check your general health. You will also have **blood tests** during your treatment.

Check with your healthcare professional or nurse before you are given Opdualag if:

- you have an active **autoimmune disease** (a condition where the body attacks its own cells);
- you have **melanoma of the eye**;
- you have been told that your **cancer has spread to your brain**;
- you have been taking **medicines to suppress your immune system**.

Other warnings you should know about:

Pregnancy and breast-feeding

Before starting Opdualag, tell your healthcare professional if you are pregnant or think you might be, if you are planning to become pregnant, or if you are breast-feeding.

Opdualag can cause harm or death to your unborn baby. You must use effective contraception while you are being treated with Opdualag and for at least 5 months following the last dose of Opdualag if you are a woman who could become pregnant.

Opdualag may pass into your breast milk. Do not breast-feed during treatment with Opdualag and for at least 5 months after your last dose of Opdualag.

Driving and using machines

Opdualag may have an influence on your ability to drive and use machines, so you should; use caution when performing these activities until you are sure that Opdualag does not adversely affect you.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may also interact with Opdualag:

No drug-drug interaction studies have been conducted with Opdualag.

Before you are given Opdualag, tell your healthcare professional if you are taking any medicines that suppress your immune system, such as corticosteroids, since these medicines may interfere with the effect of Opdualag. However, once you are treated with Opdualag, your healthcare professional may give you corticosteroids to reduce any possible side effects that you may have during your treatment.

Tell your healthcare professional if you are taking or have recently taken any other medicines. **Do not take any other medicines** during your treatment without talking to your healthcare professional first.

How to take Opdualag:

- You will receive treatment with Opdualag in a hospital or clinic, under the supervision of an experienced healthcare professional.
- Your healthcare professional will give you Opdualag into your vein through an intravenous (IV) line over 30 minutes.
- Opdualag is usually given every 4 weeks. Your healthcare provider will decide how many treatments you need.
- Your healthcare professional will do blood tests to check you for side effects.
- If you miss any appointments, call your healthcare professional as soon as possible to reschedule your appointment.

Usual dose:

The recommended dose for Adults and Pediatric patients 12 years of age or older who weigh at least 40 kg is:

- Opdualag (480 mg nivolumab and 160 mg relatlimab) every 4 weeks.

Depending on your dose, the appropriate amount of Opdualag may be diluted with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection before use. More than one vial of Opdualag may be necessary to obtain the required dose.

Overdose:

If you think you, or a person you are caring for, have taken too much Opdualag, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

If you stop using Opdualag:

Stopping your treatment may stop the effect of the medicine. Do not stop treatment with Opdualag unless you have discussed this with your healthcare professional.

If you have any further questions on the use of this medicine, ask your healthcare professional.

Missed Dose:

It is very important for you to keep all your appointments to receive Opdualag. If you miss an appointment, ask your healthcare professional when to schedule your next dose.

Possible side effects from using Opdualag:

These are not all the possible side effects you may have when taking Opdualag. If you experience any side effects not listed here, tell your healthcare professional.

Be aware of important symptoms of inflammation. Opdualag acts on your immune system and may cause inflammation in parts of your body. Inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening and need treatment or withdrawal of Opdualag.

Very common side effects (may affect more than 1 in 10 people)

- infection of the urinary tract;
- decreased number of red blood cells (which carry oxygen) and white blood cells (lymphocytes, neutrophils, leucocytes) (which are important in fighting infection);
- underactive thyroid gland (which can cause tiredness or weight gain);
- decreased appetite;
- headache;
- difficulty breathing, cough;
- diarrhea (watery, loose or soft stools), nausea, stomach pain, constipation;
- skin rash, sometimes with blisters, skin colour change in patches (vitiligo), itching;
- pain in the muscles, bones and joints;
- feeling tired or weak, fever.

Changes in the results of tests carried out by your healthcare professional may show:

- abnormal liver function (increased amounts of the liver enzymes alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase in your blood);
- abnormal kidney function (increased amounts of creatinine in your blood);
- decrease of sodium, magnesium and increase of potassium and decrease or increase of calcium in your blood.

Common side effects (may affect more than 1 in 100 people and up to 1 in 10 people)

- infections of the upper respiratory tract;

- decreased number of platelets (cells which help the blood to clot), increase in some white blood cells;
- decreased secretion of hormones produced by adrenal glands (glands situated above the kidneys), inflammation of the pituitary gland situated at the base of the brain, overactive thyroid gland, inflammation of the thyroid gland;
- diabetes, low sugar levels in the blood, weight loss, high uric acid levels in the blood, decreased levels of albumin in the blood, dehydration;
- state of confusion;
- inflammation of the nerves (causing numbness, weakness, tingling or burning pain of the arms and legs), dizziness, changes in the sense of taste;
- inflammation of the eye (which causes pain and redness, vision problems or blurry vision), vision problems, dry eyes, abnormal or excessive tears;
- inflammation of the heart muscle;
- inflammation of a vein, which can cause redness, tenderness and swelling;
- inflammation of the lungs (pneumonitis), characterised by coughing and difficulty breathing, nasal congestion;
- inflammation of the intestines (colitis), inflammation of the pancreas, inflammation of the stomach (gastritis), difficulty in swallowing, mouth ulcers and cold sores, dry mouth;
- inflammation of the liver (hepatitis);
- unusual hair loss or thinning (alopecia), isolated area of skin growth that becomes red and itchy (lichenoid keratosis), sensitivity to light, dry skin;
- painful joints (arthritis), muscle spasms, muscle weakness;
- kidney failure, high levels of proteins in the urine;
- edema (swelling), flu-like symptoms, chills;
- reactions related to the administration of the medicine.

Changes in the results of tests carried out by your healthcare professional may show:

- abnormal liver function (higher blood levels of the waste product bilirubin; higher blood levels of the liver enzyme gamma-glutamyl transferase);
- increase in sodium and magnesium;
- increased level of troponin (a protein released into the blood when the heart is damaged);
- increased level of the enzyme that breaks down glucose (sugar), the enzyme that breaks down fats, the enzyme that breaks down starch.

Uncommon side effects (may affect up to 1 in 100 people)

- inflammation and infection in the hair follicles;
- disorder in which red blood cells are destroyed faster than they can be made;
- underactive function of the pituitary gland situated at the base of the brain, underactive function of the glands producing sex hormones;
- inflammation of the brain, which may include confusion, fever, memory problems or seizures (encephalitis), a temporary inflammation of the nerves that causes pain, weakness, and paralysis in the extremities (Guillain-Barré syndrome), inflammation of the optic nerve that may cause a complete or partial loss of vision;
- an overlap of either two or three conditions including inflammation of the heart muscle (myocarditis), inflammation of the muscles (myositis), and a condition in which muscles

become weak and tire easily (myasthenia gravis) (Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome);

- an inflammatory disorder, most likely of autoimmune origin, affecting the eyes, skin and the membranes of the ears, brain and spinal cord (Vogt-Koyanagi-Harada syndrome), increase blood congestion in the eye;
- fluid around the heart;
- asthma;
- inflammation of the food pipe;
- inflammation of the bile duct;
- skin rashes and blistering on the legs, arms and abdomen (pemphigoid), skin disease with thickened patches of red skin, often with silvery scales (psoriasis), hives (itchy, bumpy rash);
- inflammation of the muscles causing weakness, swelling, and pain, disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren's syndrome), inflammation of muscles causing pain or stiffness, inflammation of the joints (painful joint disease), disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs, such as joints, skin, brain, lungs, kidneys, and blood vessels (systemic lupus erythematosus);
- inflammation of the kidney;
- absence of sperm in the semen.

Changes in the results of tests carried out by your healthcare professional may show:

- abnormal c-reactive protein increased;
- red blood cell sedimentation rate increased.

If you get any serious side effects with Opdualag, talk to your healthcare professional. Side effects may be very common (may affect more than 1 in 10 people), common (may affect less than 1 in 10 but more than 1 in 100 people), uncommon (may affect less than 1 in 100 but more than 1 in 1,000 people), or rare (may affect less than 1 in 1,000 people).

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Common			
Inflammation of the intestines (colitis) <i>Symptoms may include:</i> • diarrhea (watery, loose, or soft stools) or more bowel movements than usual. Do not treat the diarrhea yourself • stool that are black, tarry, sticky, or have blood or mucus		√	

• stomach pain (abdominal pain) or tenderness			
Inflammation of the liver (hepatitis) <i>Symptoms may include:</i> • extreme tiredness • yellowing of your skin (jaundice) or the whites of your eyes • severe nausea or vomiting • pain on the right side of your stomach (abdomen) • bruise easily or bleeding		√	
Inflammation of the lung (pneumonitis) <i>Symptoms may include:</i> • trouble breathing, shortness of breath • cough (new or worsening) with or without mucus • chest pain		√	
Inflammation of the skin (severe skin problems) <i>Symptoms may include:</i> • severe skin reactions or rash • itching • skin blistering and peeling • ulcers in the mouth or nose, throat, or genital area • raised skin lumps/bumps (skin nodules)		√	
Inflammation of the thyroid, adrenal or pituitary glands <i>Symptoms may include:</i> • headaches that will not go away or unusual • unusual tiredness or sleepiness • eye sensitivity to light • eye problems • rapid heartbeat • increased sweating • extreme tiredness		√	

• feeling more hungry or thirsty than usual • urinating more often than usual • hair loss • feeling cold • constipation • your voice gets deeper • weight changes (weight gain or weight loss) • changes in mood or behaviour such as less sex drive, being irritable or forgetful, or depression • dizziness or fainting			
Inflammation of the heart muscle (myocarditis) • new or worsening chest pain • palpitations • shortness of breath • fatigue • swelling in ankles		√	
Blood sugar problems (diabetes or ketoacidosis) <i>Symptoms may include:</i> • hunger or excessive thirst • need to urinate more often • increased appetite with weight loss, or loss of appetite • muscle weakness • sleepiness or drowsiness • depression • irritability • feeling unwell		√	
Inflammation of the nerves <i>Symptoms may include:</i> • muscle weakness • muscle stiffness • numbness • loss of reflexes • uncoordinated movements		√	
Inflammation of the eye <i>Symptoms may include:</i>		√	

• changes in eyesight • eye pain or redness • blurred or blurry vision, or other vision problems			
Uncommon			
Inflammation of the kidney (nephritis) <i>Symptoms may include:</i> • changes in urine output (increase or decrease) • blood in the urine or dark urine (tea-coloured) • swelling of ankles • loss of appetite		√	
Inflammation of the brain (encephalitis) <i>Symptoms may include:</i> • headache • fever • confusion • memory problems • sleepiness or drowsiness • seeing things that are not really there (hallucinations) • seizures (fits) • stiff neck		√	
Inflammation of the muscles (myositis): <i>Symptoms may include:</i> • muscle or joint pain, stiffness, or weakness		√	
Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome: <i>Overlap of two or three of the following Symptoms:</i> • Inflammation of the heart muscle (myocarditis) • inflammation of the muscles (myositis) • muscles become weak and tire easily (myasthenia gravis)		√	

Other serious side effects include:

Haemophagocytic lymphohistiocytosis. A rare disease in which your immune system makes too many of otherwise normal infection fighting cells called histiocytes and lymphocytes. Symptoms may include enlarged liver and/or spleen, skin rash, lymph node enlargement, breathing problems, easy bruising, kidney abnormalities, and heart problems.

Severe infusion reactions may occur (common: more than 1 in 100 to less than 1 in 10). Symptoms may include chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, or feeling like passing out.

Complications of stem cell transplant that uses donor stem cells (allogeneic) in patients treated with nivolumab before or after transplant. These complications can be severe and can lead to death. Your healthcare professional will monitor you for signs of complications if you have an allogeneic stem cell transplant. If you are having a stem cell transplant, tell your transplant doctor that you have received nivolumab in the past.

Also tell your healthcare professional before you are given Opdualag if you have received an allogeneic stem cell transplant.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

It is unlikely that you will be asked to store Opdualag yourself. It will be stored in the hospital or clinic where it is given to you.

Keep out of reach and sight of children.

Do not use Opdualag after the expiry date which is stated on the carton and the vial label after EXP.

The expiry date refers to the last day of that month.

Store in a refrigerator (2°C to 8°C). Do not freeze.

Store in the original package in order to protect from light.

The unopened vials can be stored at controlled room temperature up to 25°C with room light for up to 72 hours.

Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.

Keep out of reach and sight of children.

If you want more information about Opdualag:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database ([Drug Product Database: Access the database](#)); the manufacturer's website [Bristol-Myers Squibb Canada](#); or by calling 1-866-463-6267.

This leaflet was prepared by Bristol-Myers Squibb Canada.

Date of Authorization: 2026-09-11

®Opdualag is a registered trademark of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada.